Recruiting OBSERVATIONAL NCT06531109

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib (PRESTO)

PRESTO - Characterization and Clinical Outcomes of Alopecia Aerata (AA) Patients Treated With Ritlecitinib in a Real-world (RW) Cohort: A Multinational, Prospective Observational Study.

Sponsor: Pfizer

Conditions Alopecia Areata

Interventions Ritlecitinib

Updated 9 times since 2024 Last updated: Feb 19, 2026 Started: Aug 7, 2024 Primary completion: Mar 31, 2028 Completion: Mar 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Alopecia Areata, this trial is actively recruiting participants. The trial is conducted by Pfizer and has accumulated 9 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Recruiting
Sep 2025 — Feb 2026 [monthly]

Recruiting
Mar 2025 — Sep 2025 [monthly]

Recruiting
Feb 2025 — Mar 2025 [monthly]

Recruiting
Dec 2024 — Feb 2025 [monthly]

Recruiting

▶ Show 4 earlier versions

Nov 2024 — Dec 2024 [monthly]

Recruiting
Oct 2024 — Nov 2024 [monthly]

Recruiting
Sep 2024 — Oct 2024 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Argenteuil, France , Auburn Hills, United States , Bath, United Kingdom , Beijing, China , Boca Raton, United States , Boston, United States , Brighton, United Kingdom , Bunkyo-ku, Japan , Burlington, United States , Caen, France and 42 more locations